E. Ohman J or Asset Management AB decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 3.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,461 shares of the medical research company’s stock after selling 240 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in IQVIA were worth $1,768,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of the company. Investment Research & Advisory Group Inc. lifted its stake in shares of IQVIA by 1.9% during the 3rd quarter. Investment Research & Advisory Group Inc. now owns 17,843 shares of the medical research company’s stock valued at $4,228,000 after buying an additional 328 shares in the last quarter. IFM Investors Pty Ltd increased its holdings in IQVIA by 2.3% in the 3rd quarter. IFM Investors Pty Ltd now owns 37,176 shares of the medical research company’s stock valued at $8,810,000 after acquiring an additional 835 shares during the last quarter. Bogart Wealth LLC increased its holdings in IQVIA by 80.5% in the 3rd quarter. Bogart Wealth LLC now owns 36,566 shares of the medical research company’s stock valued at $8,665,000 after acquiring an additional 16,305 shares during the last quarter. CENTRAL TRUST Co increased its holdings in IQVIA by 35.0% in the 3rd quarter. CENTRAL TRUST Co now owns 690 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 179 shares during the last quarter. Finally, Great Lakes Retirement Inc. increased its holdings in IQVIA by 6.3% in the 3rd quarter. Great Lakes Retirement Inc. now owns 2,876 shares of the medical research company’s stock valued at $682,000 after acquiring an additional 170 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.
IQVIA Price Performance
IQVIA stock opened at $214.63 on Friday. The stock has a market cap of $39.11 billion, a price-to-earnings ratio of 29.32, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a 50-day moving average of $238.13 and a two-hundred day moving average of $230.78.
Analyst Upgrades and Downgrades
View Our Latest Analysis on IQVIA
Insider Transactions at IQVIA
In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.60% of the company’s stock.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
- Five stocks we like better than IQVIA
- Business Services Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- Investing in Commodities: What Are They? How to Invest in Them
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Read Stock Charts for Beginners
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.